Antihypertensive therapy in hypertrophic cardiomyopathy.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  American Journal of Cardiology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjcard.2012.12.026PMID 23340036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.

  2012cited by this paper
• 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cited by this paper
• Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity.

  2011cited by this paper
• US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008

  2011cited by this paper
• 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci

  2011cited by this paper
• US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.

  2010cited by this paper
• Severe Symptoms in Mid and Apical Hypertrophic Cardiomyopathy

  2009cited by this paper
• Management of Symptoms in Hypertrophic Cardiomyopathy

  2008cited by this paper
• Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction

  2006cited by this paper
• Single-Gene Mutations and Increased Left Ventricular Wall Thickness in the Community: The Framingham Heart Study

  2006cited by this paper
• Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.

  2005cited by this paper
• Biphasic left ventricular outflow and its mechanism in hypertrophic obstructive cardiomyopathy.

  2004cited by this paper
• Safety of stress testing in patients with hypertrophic cardiomyopathy.

  2004cited by this paper
• American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G

  2003cited by this paper
• American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G

  2003cited by this paper
• Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy

  2003cited by this paper
• Hypertrophic cardiomyopathy: a systematic review.

  2002cited by this paper
• Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.

  2000cited by this paper
• Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy.

  1998cited by this paper
• Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy.

  1998cited by this paper
• Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the Cardia Study

  1996cited by this paper
• Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.

  1995cited by this paper
• Hypertrophic cardiomyopathy. Clinical spectrum and treatment.

  1995cited by this paper
• Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise.

  1992cited by this paper
• Diversity of patterns of hypertrophy in patients with systemic hypertension and marked left ventricular wall thickening.

  1990cited by this paper
• Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy.

  1988cited by this paper
• Hypertensive hypertrophic cardiomyopathy of the elderly.

  1987cited by this paper
• Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography.

  1985cited by this paper
• Hypertensive hypertrophic cardiomyopathy of the elderly.

  1985cited by this paper
• Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.

  1981cited by this paper

• The role of diagnostic modalities in differentiating hypertensive heart disease and hypertrophic cardiomyopathy: strategies in adults for potential application in paediatrics.

  2025cites this paper
• Medical, Surgical, and Interventional Management of Hypertrophic Cardiomyopathy

  2025cites this paper
• Clinical course of adults with co-occurring hypertrophic cardiomyopathy and hypertension: A scoping review

  2024influential citation
• Medical Treatment Strategies for Hypertrophic Cardiomyopathy.

  2024cites this paper
• Clinical course and outcomes in adults with co-occurring hypertrophic cardiomyopathy and hypertension: a scoping review protocol

  2023cites this paper
• Medical therapies for hypertrophic cardiomyopathy: Current state of the art.

  2023cites this paper
• The impact of hypertension on the prognosis of patients with hypertrophic cardiomyopathy: a single-center retrospective study

  2023cites this paper
• The use of attention-deficit hyperactivity disorder medications in cardiac disease

  2022cites this paper
• Appendix: General review questions

  2022cites this paper
• 2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

  2021cites this paper
• 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2021cites this paper
• 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2020cites this paper
• Sex-Related Differences in the Impact of Systemic Hypertension on Left Ventricular Remodeling in Patients with Hypertrophic Obstructive Cardiomyopathy

  2020cites this paper
• Abnormalities in Sodium Current and Calcium Homeostasis as Drivers of Arrhythmogenesis in Hypertrophic Cardiomyopathy.

  2020cites this paper
• 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2020cites this paper
• Correction to: 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2020cites this paper
• Fibrosis in Disease

  2019cites this paper
• Hypertrophic Cardiomyopathy

  2019influential citation
• The effect of hypertension on cardiac structure and function in different types of hypertrophic cardiomyopathy: A single-center retrospective study

  2018cites this paper
• Fibrotic Signaling in Cardiomyopathies

  2018cites this paper
• Medical Therapy: From Beta-Blockers to Disopyramide

  2018cites this paper
• Lifestyle Modification: Diet, Exercise, Sports, and Other Issues

  2018cites this paper
• 54-Year-Old Woman With Progressive Dyspnea on Exertion and Syncopal Episodes.

  2017cites this paper
• Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy

  2017cites this paper
• An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives.

  2016cites this paper
• Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

  2016cites this paper
• Erratum to: Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction

  2016cites this paper
• Misconceptions and Facts About Hypertrophic Cardiomyopathy.

  2016cites this paper
• Mid-Cavity Obstruction and High Intraventricular Pressure in Child with Critical Hypertrophic Cardiomyopathy

  2015cites this paper
• Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction

  2015cites this paper
• Medical Therapy: From Beta–Blockers to Disopyramide

  2015cites this paper
• Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.

  2014cites this paper